Low UPB1 Level Correlates With Poor Prognosis in Lung Adenocarcinoma
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Low UPB1 Level Correlates With Poor Prognosis in Lung Adenocarcinoma
Authors
Keywords
-
Journal
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
Volume -, Issue -, Pages -
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2023-10-20
DOI
10.1097/pai.0000000000001159
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Outcomes in Patients With Lung Adenocarcinoma With Transformation to Small Cell Lung Cancer After EGFR Tyrosine Kinase Inhibitors Resistance: A Systematic Review and Pooled Analysis
- (2022) Jinhe Xu et al. Frontiers in Oncology
- UALCAN: An update to the integrated cancer data analysis platform
- (2022) Darshan Shimoga Chandrashekar et al. NEOPLASIA
- An immune-related microRNA signature prognostic model for pancreatic carcinoma and association with immune microenvironment
- (2022) Qian Shen et al. Scientific Reports
- A robust CD8+ T cell-related classifier for predicting the prognosis and efficacy of immunotherapy in stage III lung adenocarcinoma
- (2022) Jinteng Feng et al. Frontiers in Immunology
- Integrative pan-cancer analysis and clinical characterization of the N7-methylguanosine (m7G) RNA modification regulators in human cancers
- (2022) Chun-Ming He et al. Frontiers in Genetics
- Immune Resistance in Lung Adenocarcinoma
- (2021) Magda Spella et al. Cancers
- Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival
- (2021) Ana Casal-Mouriño et al. Translational Lung Cancer Research
- Cancer statistics for the year 2020: An overview
- (2021) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Strategies to overcome resistance to immune checkpoint blockade in lung cancer
- (2021) Ilaria Attili et al. LUNG CANCER
- Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review
- (2021) Alessandro Leonetti et al. Frontiers in Oncology
- A 13-gene risk score system and a nomogram survival model for predicting the prognosis of clear cell renal cell carcinoma
- (2020) Chao Zhang et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- TIMER2.0 for analysis of tumor-infiltrating immune cells
- (2020) Taiwen Li et al. NUCLEIC ACIDS RESEARCH
- TISIDB: an integrated repository portal for tumor-immune system interactions
- (2019) Beibei Ru et al. BIOINFORMATICS
- Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
- (2019) Narjust Duma et al. MAYO CLINIC PROCEEDINGS
- Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups
- (2019) Lawrence P. Andrews et al. NATURE IMMUNOLOGY
- Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer
- (2017) Misako Nagasaka et al. Expert Review of Anticancer Therapy
- UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
- (2017) Darshan S. Chandrashekar et al. NEOPLASIA
- Development and Validation of a Three-gene Prognostic Signature for Patients with Hepatocellular Carcinoma
- (2017) Binghua Li et al. Scientific Reports
- Identification of Circulating Biomarker Candidates for Hepatocellular Carcinoma (HCC): An Integrated Prioritization Approach
- (2015) Faryal Mehwish Awan et al. PLoS One
- Contribution of the β-ureidopropionase (UPB1) gene alterations to the development of fluoropyrimidine-related toxicity
- (2014) Julie Fidlerova et al. Pharmacological Reports
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started